ESC Professional Premium Access

Anti-diabetic pharmacotherapy in clinical practice

Event: ESC Congress 2022
Topic: Antidiabetic Pharmacotherapy
Session type: Moderated ePosters
Date: 27 August 2022
Time: 15:15 - 15:55

Congress Session

6 presentations in this session

The DPP4 inhibitor linagliptin exacerbated heart failure due to energy deficiency via downregulation of glucose absorption and utilization in mice.

Speaker: Doctor A. Shiraki (Saga, JP)

Empagliflozin rescues primary murine cardiac fibroblasts, but not cardiomyocytes, from hypoxia-reoxygenation injury through STAT3-mediated cascades.

Speaker: Mrs P. Nikolaou (Athens, GR)

Anti-inflammatory potential of SGLT2 inhibitors: a systematic review and meta-analysis of preclinical studies in rodents

Speaker: Doctor M. Sagris (Athens, GR)

Four-months treatment with dapagliflozin improves endothelial glycocalyx and cardiovascular function in patients with type 1 diabetes mellitus.

Speaker: Doctor I. Ikonomidis (Athens, GR)

Absolute treatment effects for the primary outcome and all-cause mortality in the cardiovascular outcome trials in type 2 diabetes: a meta-analysis of individual patient data

Speaker: Mr G. Wolff (Duesseldorf, DE)

Adherence and discontinuation of sglt2-inhibitors and glp1-r agonists in patients with type 2 diabetes with and without cardiovascular disease

Speaker: Doctor M. Malik (Copenhagen, DK)
Speaker: Doctor A. Falkentoft (Roskilde, DK)

7 speakers from this session

Doctor Aya Shiraki

Saga University, Saga (Japan)
0 follower

Mrs Panagiota Nikolaou

National & Kapodistrian University of Athens, Athens (Greece)
1 follower

Doctor Marios Sagris

Hippokration General Hospital, Athens (Greece)
0 follower

Doctor Ignatios Ikonomidis

National & Kapodistrian University of Athens, Athens (Greece)
5 presentations

Mr Georg Wolff

University Hospital Duesseldorf, Duesseldorf (Germany)
0 follower

Doctor Mariam Elmegaard Malik

Gentofte University Hospital, Copenhagen (Denmark)
0 follower

Doctor Alexander Christian Falkentoft

Zealand University Hospital, Roskilde (Denmark)
1 presentation
0 follower

This platform is supported by

logo Novo Nordisk